We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants ...We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants with self-reported coronary heart disease （CHD） and 872 with stroke, nearly 80% of individuals with CHD and 73% of individuals with stroke were not taking any proven secondary prevention drug. However, 32.9% of them took TCM products. Patients with CVDs in rural areas used less secondary prevention treatment, but more TCM products than their counterparts in the urban regions. After adjusting for confounding factors, lower rates of secondary prevention treatment were evident in Western China compared with Eastern China, which was more developed. Systematic change is needed to promote the development of evidence-based medicine at the community level in China.展开更多
文摘We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants with self-reported coronary heart disease （CHD） and 872 with stroke, nearly 80% of individuals with CHD and 73% of individuals with stroke were not taking any proven secondary prevention drug. However, 32.9% of them took TCM products. Patients with CVDs in rural areas used less secondary prevention treatment, but more TCM products than their counterparts in the urban regions. After adjusting for confounding factors, lower rates of secondary prevention treatment were evident in Western China compared with Eastern China, which was more developed. Systematic change is needed to promote the development of evidence-based medicine at the community level in China.
